For most licensed medicines that reach the NHS in England, the route to routine clinical use runs through the NICE single technology appraisal (STA) process: a structured assessment of clinical and cost-effectiveness that applies a cost-per-quality-adjusted-life-year (QALY) threshold of £20,000 to £30,000 as its primary decision criterion. That threshold, and the population health economics framework it represents, was designed for medicines used in large patient groups where the cost-per-QALY calculation is supported by substantial trial data and a well-characterised comparator landscape.
Rare diseases and the orphan drugs developed to treat them fit neither of those assumptions. Patient populations may be measured in hundreds rather than thousands. Clinical trial programmes are constrained by the limited number of eligible patients worldwide, often producing open-label, single-arm, or historically controlled datasets that are structurally different from the phase 3 RCT evidence that underpins standard NICE appraisals. The cost-per-patient cost of development is distributed across a small patient population, producing list prices that would generate ICERs of several hundred thousand pounds per QALY under the standard STA methodology, a figure that would automatically trigger a NICE 'not recommended' conclusion under ordinary criteria regardless of clinical benefit.
The NICE Highly Specialised Technologies (HST) programme exists precisely because applying the standard STA framework to ultra-rare disease treatments produces outcomes that NICE itself considers neither fair to patients nor consistent with the NHS's commitment to treating rare and common diseases within a single healthcare system.
What Makes a Technology Eligible for the HST Programme
NICE applies specific criteria to determine whether a technology qualifies for the HST route rather than the standard STA pathway. The condition must affect no more than 1 in 50,000 people in England, the conventional definition of an ultra-rare disease in the NICE framework. Treatment must typically be provided in a small number of highly specialised NHS centres rather than in general secondary care. The technology must be an innovative treatment for a condition with a very high burden of disease, where existing treatment options are absent or severely limited.
These criteria are not formalities. NICE actively gates eligibility and can redirect a manufacturer's submission from the HST to the STA route if the patient population is larger than declared or if treatment delivery is not genuinely restricted to specialised centres. The commercial consequence of this gatekeeping is significant: a technology assessed under STA and failing the £20,000 to £30,000 QALY threshold has no automatic second route; a technology correctly assessed under HST benefits from a substantially different cost-effectiveness framework.
The MHRA orphan designation, a separate regulatory designation that applies when the disease affects fewer than 5 in 10,000 people in the EU, or fewer than 5 in 10,000 in the UK under post-Brexit MHRA criteria, is related but not equivalent to NICE HST eligibility. A drug with MHRA orphan designation is not automatically eligible for the HST route, and a drug without orphan designation may in principle qualify if the ultra-rare disease criteria are met. The two processes are conducted by different bodies under different criteria and should not be conflated.
How the Cost-Effectiveness Framework Differs
Under the standard STA framework, NICE's cost-effectiveness threshold is £20,000 to £30,000 per QALY gained. Technologies generating ICERs above £30,000 per QALY face increasing evidential requirements to justify a positive recommendation, and those above approximately £50,000 per QALY are rarely recommended through the standard route without a patient access scheme reducing the net cost.
Under the HST framework, NICE applies an explicit QALY weighting approach that allows ICERs of up to £100,000 per QALY to be considered acceptable, and in some circumstances higher still, depending on the degree of QALY shortfall in the untreated condition and the magnitude of benefit the technology delivers. This weighting reflects NICE's judgement that a QALY gained by a person with an ultra-rare disease carries greater value to that individual and to society than the standard QALY calculation implies, because the untreated condition typically involves very high disease burden concentrated in a small, identifiable population with very few alternatives.
The practical consequence for manufacturers is that HST submissions require a cost-effectiveness analysis calibrated to the £100,000 per QALY ceiling rather than the standard threshold. Negotiations between NICE, NHS England, and the manufacturer may still produce a commercial access agreement or patient access scheme below list price, but the starting framework for the negotiation is fundamentally different, and the probability of a positive recommendation for a technology with genuinely transformative clinical outcomes in ultra-rare disease is substantially higher under HST than under STA.
NICE's highest HST cost-effectiveness threshold of approximately £100,000 per QALY represents a more than three-fold increase over the standard STA upper threshold of £30,000 per QALY, a differential that reflects the structural difference in clinical trial evidence quality, patient population size, and individual disease burden in ultra-rare conditions.
Recent HST Decisions and What They Illustrate
The HST programme has produced decisions across a range of ultra-rare disease areas that illustrate both its scope and its limits. Enzyme replacement and related therapies for lysosomal storage and neurometabolic disorders have been assessed under the HST route, with outcomes ranging from positive recommendations with managed access agreements to negative decisions where the price could not be justified even under the widened HST framework. Cerliponase alfa (Brineura) for neuronal ceroid lipofuscinosis type 2, a form of Batten disease, illustrates the full arc: NICE recommended it in 2019 under a five-year managed access agreement so treatment could begin while longer-term data were collected, and when that period ended NICE's 2026 review did not recommend continued routine NHS funding at the proposed price. The case shows that the HST route widens the cost-effectiveness framework but does not guarantee open-ended access.
For spinal muscular atrophy (SMA), the onasemnogene abeparvovec (Zolgensma; Novartis) HST assessment in 2021 produced a managed access agreement following initial NICE appraisal that concluded list price was not cost-effective even at the HST threshold. The managed access agreement, a commercial arrangement under which Novartis receives payment conditional on patient outcomes data demonstrating that the one-time gene therapy produces durable benefit, represents the most sophisticated form of outcome-contingent NHS access agreement yet negotiated for a rare disease treatment, and it has become a template for subsequent gene therapy negotiations. The per-patient list price of onasemnogene abeparvovec at the time of the HST assessment was approximately £1.79 million, a figure that illustrates both the commercial reality of gene therapy economics and the inadequacy of any fixed QALY threshold applied without a flexible pricing mechanism.
Atidarsagene autotemcel (Libmeldy; Orchard Therapeutics) for metachromatic leukodystrophy shows the positive end of that spectrum: NICE recommended it through the HST route in March 2022 under a confidential commercial arrangement, making what was then the most expensive medicine NICE had ever appraised routinely available to eligible children. The contrast is betibeglogene autotemcel (Zynteglo; bluebird bio) for transfusion-dependent beta-thalassaemia, which NICE assessed through the standard single technology appraisal route rather than HST, did not recommend on cost-effectiveness grounds, and which the manufacturer subsequently withdrew from the European market. Together the two cases confirm that gene therapies with transformative but evidence-limited efficacy profiles reach NHS patients only where an outcome-contingent or discounted commercial framework can bridge the gap between list price and what the cost-effectiveness assessment will bear, and that the choice of appraisal route (HST versus STA) can be decisive.
The Access Gap Between MHRA Authorisation and NHS Availability
The NICE HST process adds a median of 12 to 18 months to the time between MHRA marketing authorisation and routine NHS availability a gap that is experienced most acutely by patients with rapidly progressive ultra-rare diseases where months of delay have clinical consequence. The Cancer Drugs Fund and the Innovative Medicines Fund provide interim access mechanisms for oncology and non-oncology treatments respectively while NICE appraisals are completed, but their applicability to HST-eligible technologies is variable and not automatic.
For pharmaceutical companies seeking UK market access for orphan or ultra-rare disease treatments, the strategic implication is that MHRA authorisation should be pursued in parallel with NICE HST pre-submission meetings, which NICE offers to facilitate commercial and evidence preparation. Early NICE engagement, typically 12 to 24 months before the anticipated marketing authorisation, substantially reduces the access gap and gives manufacturers the opportunity to align their health economic model with NICE's accepted methodology before the formal submission. Companies that submit an HST dossier to NICE simultaneously with or shortly after MHRA authorisation consistently achieve faster positive guidance than those that treat regulatory approval as a precondition before health economic preparation begins.
What Patients and Clinicians Should Know
For clinicians managing patients with ultra-rare diseases, the practical implication of the HST process is that the timeline from diagnosis to treatment access where a licensed treatment exists involves multiple sequential decisions, not a single approval event. MHRA authorisation means the treatment is licensed and can legally be prescribed; it does not mean it is funded. NICE HST guidance means it is recommended for NHS use; it does not always mean it is immediately available at all treating centres. A managed access agreement means a treatment pathway exists but may involve data collection obligations, designated centre requirements, and periodic access reviews.
Clinicians should not assume that a positive NICE HST recommendation translates automatically into funded access at their institution within weeks. NHS England's commissioning implementation process, the designation of specialist centres, the supply chain readiness of the manufacturer, and the administrative steps required to activate Blueteq or equivalent criteria forms all add time between NICE guidance publication and first patient treatment. For patients with months rather than years of remaining functional capacity before disease progression, every step in this process deserves active clinical advocacy.
The HST programme is the NHS's most sophisticated attempt to reconcile a population-health cost-effectiveness framework with the reality that some diseases affect too few people to fit within it. Whether the £100,000 per QALY threshold is generous enough or whether even that ceiling fails some genuinely transformative gene therapies at list price is the central policy question in rare disease access that has not yet been definitively answered.
Related reading
MHRA Approves Obecabtagene Autoleucel for Relapsed B-Cell Leukaemia
Pembrolizumab Gains NICE Backing for Earlier Lung Cancer
What the New UK Clinical Trials Regulations Mean for Sponsors
